Table 3.
Peptide | Sequence | Purity (%) | TRBV | CDR3 Beta | TRAV | CDR3 Alpha | |
---|---|---|---|---|---|---|---|
TCC 1 | 31–50 | SCLSSQSSALSQSGGGSTSA | 100 | 11-2 | CASSLGAGGYTEAFF | 8-3*01 | CAVGGAGNMLTF |
TCC 2 | 51–70 | AGIEARSRALRRRWCPAGIM | 98 | 10-3 | CAISDGISGNTIYF | 14 | CAMRVGSDGQKLLF |
TCC 3 | 1–20 | MVSALRGAPLIRVHSSPVSS | – | – | – | – | – |
TCC 4 | 111–130 | SLADWVCLAYFTSGFNAAAL | 99 | 12 | CASSLTENIQYF | 13-1 | CAASSGGSNYKLTF |
TCC 5 | 51–70 | AGIEARSRALRRRWCPAGIM | – | 12-4 | CASSFGQPNLNYGYTF | 19 | CALSEAGFQKLVF |
Naming of TCR chains according to IMGT nomenclature. SLLP1 peptide and CDR3 sequence are displayed using amino acid single letter code. T cell clone purity was determined by flow cytometry.
TRBV/TRAV T cell receptor variable beta/alpha chain, CDR3 complementarity determining region 3.